Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 544

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 544
---
877) 870 -8565
Main Telephone: (206) 870 -8565
E -mail: ksmith@advantageproxy.com If you are a stockholder of BLAC and would like to request documents, please do so by no later than five business days before the BLAC Stockholders’ Meeting in order to receive them before such special meeting.If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means. All information contained in this proxy statement/prospectus relating to BLAC has been supplied by BLAC, and all such information relating to OSR Holdings has been supplied by OSR Holdings. Information provided by either BLAC or OSR Holdings does not constitute any representation, estimate or projection of any other party. This document is a proxy statement of BLAC for the BLAC Stockholders’ Meeting. We have not authorized anyone to give any information or make any representation about the Business Combination, us or OSR Holdings that is different from, or in addition to, that contained in this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. The information contained in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies. 345

INDEX TO FINANCIAL STATEMENTS

| Bellevue Life Sciences Acquisition Corp. Unaudited Condensed Financial Statements                                                    
 Condensed Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023                                                  
 Condensed Statements of Operations (unaudited) for the three and nine months ended September 30, 2024 and 2023                       |     | Page  
 F-2   
 F-3   |
|:-------------------------------------------------------------------------------------------------------------------------------------|:----|:------|
| Condensed Statements of Changes in Stockholders’ Deficit (unaudited) for the three and nine months ended September 30, 2024 and 2023 |     | F-4   |
| Condensed Statements of Cash Flows (unaudited) for the nine months ended September 30, 2024 and 2023                                 |     | F-5   |
| Notes to Condensed Financial Statements (unaudited)                                                                                  |     | F-6   |
| Bellevue Life Sciences Acquisition Corp. Audited Financial Statements                                                                |     |       |
| Report of Independent Registered Public Accounting